prostate cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: a) patients with prostate cancer who need surgical treatment. b) confirmed by traditional imaging (bone imaging, CT or MRI) or PET/CT that there was no non-regional lymph node metastasis, bone metastasis or other site metastasis (such as visceral metastasis), namely M0. c) patients with pelvic lymph node metastasis (N1) are allowed to enter the group. d) 18 years old = age = 80 years old. e) through preoperative communication, the patients and their families indicated that they were fully aware of the disease and the choice of treatment and signed the informed consent form and informed choice notice.
Exclusion criteria
Exclusion criteria: a) patients who do not sign informed consent and cannot cooperate with the study. b) patients who cannot tolerate PET/CT or RLRP. c) have previously received any of the following treatments for prostate cancer: ? systemic therapy, including but not limited to: ADT therapy for more than 2 months, traditional endocrine therapy for more than 2 months, new endocrine therapy, chemotherapy, immunotherapy, targeted therapy. ? local treatment, including but not limited to pelvic radiotherapy and surgery for prostate cancer. D) malignant tumors other than prostate cancer in the past 5 years or at the same time
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Consistency between intraoperative fluoroscopic pelvic lymph nodes (positive or negative) and histopathological findings (benign or malignant); | — |
Secondary
| Measure | Time frame |
|---|---|
| positive surgical margin;Consistency between intraoperative fluoroscopic pelvic lymph nodes (positive or negative) and histopathological findings (benign or malignant); | — |
Countries
China
Contacts
Peking University First Hospital